BioWorld

June 13, 2003

View Archived Issues

Mouse Leukemic Virus, HIV Rank First, Second In Gene Therapy Sweepstakes - But Oops Factor!

Onyx Cuts Staff Further, Shifts Entire Focus To Bayer Program

InterMune Falls On Lowered Guidance; Reports Positive Data

Durect Seeking $50M Through Offering Of Convertible Notes

Northfield Gets Positive News On Blood Product; Hemosol Set Back

Other News To Note

Pozen Licenses Migraine Drug To GSK In Potential $160M Deal

Pozen Inc. could garner up to at least $160 million after entering a deal with GlaxoSmithKline plc surrounding a migraine treatment. (BioWorld Today) Read More

Maxim Gets Back On Track After Reporting Positive Ceplene Data

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...